TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days.

Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days. 

News | Hemodynamic Support Devices | November 12, 2020
November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE (...
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.

Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials...
Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system. #TCT2020 #TCTconnect

Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system.
 

News | Pulmonary Embolism | October 23, 2020
October 23, 2020 —  Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world...
Example of FFR assessment of the coronary hemodynamic flow in lesions using the Philips FFR, iFR assessment system. #FFR #TCTconnect #TCT2020

FFR assessment of a coronary lesion using the Philips Healthcare Volcano FFR system.

News | FFR Technologies | October 23, 2020
October 23, 2020 – A new observational study of deferred lesions following combined fractional flow reserve (FFR) and...
Fractional Flow reserve (FFR) selection on the Abbott, St. Jude FFR system console. The TARGET FFR study at #TCT2020 #TCTconnect.
News | FFR Technologies | October 23, 2020
October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided...
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone actually was not flow limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings. #TCT2020 #TCTconnect

An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

News | FFR Technologies | October 22, 2020 | Dave Fornell, Editor
October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from...
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS  study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates.

Feature | Stents | October 22, 2020 | Dave Fornell, Editor
October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable...
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents | October 22, 2020
October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology...
Videos | Hemodynamic Support Devices | October 20, 2020
Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the...
Videos | Cath Lab | October 19, 2020
Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ...
Videos | Stents Drug Eluting | October 19, 2020
Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ...
Videos | Antiplatelet and Anticoagulation Therapies | October 19, 2020
The COMPARE CRUSH Trial looked at the effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned...
Videos | Heart Valve Technology | October 19, 2020
David Cohen, M.D., presents late-breaking data from the STS/ACC Transcatheter Valve Registry (TVT) showing the impact...
Videos | Antiplatelet and Anticoagulation Therapies | October 19, 2020
Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use...
Videos | Heart Valve Technology | October 19, 2020
Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local...